StockData

Generate Biomedicines, Inc. (GENB) stock

GENBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$9.84−0.65 (-6.20%)

Close on Nov 17, 2026Market cap $1.26BP/E –Yield –

Generate Biomedicines r&d expenses

Research and development expenses are spending on new products and technology.

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$82.25M+37.7%
Q2 FY2026Jun 30, 2026$64.33M+37.4%
Q1 FY2026Mar 31, 2026$57.81M–
Q3 FY2025Sep 30, 2025$62.15M–
Q2 FY2025Jun 30, 2025$59.74M–
Q1 FY2025Mar 31, 2025$46.83M–

More Generate Biomedicines figures

See a number that looks wrong?